A significant increase of HLA-DR3 and DR2 in systemic lupus erythematosus among blacks.
We found a highly significant increase in the incidence of HLA-DR3 and DR2 antigens in black patients with systemic lupus erythematosus (SLE). HLA-DR3 was found in 62% of patients and 20% of controls (p less than 0.0001), and DR2 in 41% of patients and 18% of controls (p less than 0.001). The relative risk (RR), conferred by DR3 was 6.41, and that by DR2 was 3.03. Further, 84% of the patients had DR3 and/or DR2; the combined RR for SLE with these antigens was 9.0. A significant proportion of the patients (57%) developed lymphocytotoxic antibodies; of these, 19% had HLA specific antibodies.
D000017:ABO Blood-Group System / Q000276:immunology; D000328:Adult; D000368:Aged; D000974:Antibodies, Antinuclear / Q000032:analysis; D000961:Antilymphocyte Serum / Q000032:analysis; D044383:Black People; D005260:Female; D006684:HLA-DR Antigens; D015803:HLA-DR3 Antigen; D000949:Histocompatibility Antigens Class II / Q000235:genetics*; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000235:genetics / Q000276:immunology*; D008214:Lymphocytes / Q000276:immunology; D008285:Major Histocompatibility Complex; D008297:Male; D008875:Middle Aged; D012306:Risk
D000017:ABO Blood-Group System; D000974:Antibodies, Antinuclear; D000961:Antilymphocyte Serum; D006684:HLA-DR Antigens; D015803:HLA-DR3 Antigen; D000949:Histocompatibility Antigens Class II